États-Unis - anglais - NLM (National Library of Medicine)

cipla usa inc. - bleomycin sulfate (unii: 7dp3ntv15t) (bleomycin - unii:40s1vhn69b) - bleomycin for injection should be considered a palliative treatment. it has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: squamous cell carcinoma: head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. the response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. lymphomas: hodgkin's disease, non-hodgkin's lymphoma. testicular carcinoma: embryonal cell, choriocarcinoma, and teratocarcinoma. bleomycin for injection has also been shown to be useful in the management of: malignant pleural effusion: bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. bleomycin for injection is contraindicated in patients who have demonstrated

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - ingenol mebutate 0.015%{relative} ((70 µg per tube)) - topical gel - 0.015% w/w - active: ingenol mebutate 0.015%{relative} ((70 µg per tube)) excipient: benzyl alcohol citric acid monohydrate hyetellose isopropyl alcohol purified water sodium citrate dihydrate - topical treatment of solar (actinic) keratoses in adults

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - ingenol mebutate 0.05%{relative} ((235 µg per tube)) - topical gel - 0.05% w/w - active: ingenol mebutate 0.05%{relative} ((235 µg per tube)) excipient: benzyl alcohol citric acid monohydrate hyetellose isopropyl alcohol purified water sodium citrate dihydrate - topical treatment of solar (actinic) keratoses in adults

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - sodium fusidate 250mg; sodium fusidate 250mg - film coated tablet - 250 mg - active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone gelatin hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone dl-alpha tocopheryl acetate hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of localised as well as generalised staphylococcal infections (e.g. abscesses, furunculosis, wound infections, pneumonia, peritonitis, osteomyelitis, septicaemia, enteritis and otorhinolaryngeal infections).

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - calcipotriol 50 µg/g - topical cream - 50 mcg/g - active: calcipotriol 50 µg/g excipient: cetomacrogol 1000 cetostearyl alcohol dibasic sodium phosphate dihydrate disodium edetate dihydrate glycerol liquid paraffin n-(3-chloroallyl)hexaminium chloride purified water white soft paraffin

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

leo pharma limited - calcipotriol 50 µg/ml - topical solution - 50 mcg/g - active: calcipotriol 50 µg/ml excipient: hyprolose isopropyl alcohol levomenthol propylene glycol purified water sodium citrate dihydrate

États-Unis - anglais - NLM (National Library of Medicine)

macleods pharmaceuticals limited - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole 20 mg - pantoprazole sodium delayed-release tablets are indicated for: pantoprazole sodium delayed-release tablets are  indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium delayed-release tablets are  indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium delayed-release tablets are  indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. • pantoprazole sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to any component of the for

États-Unis - anglais - NLM (National Library of Medicine)

macleods pharmaceuticals limited - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets, usp are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate sodium tablets, usp reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets, usp are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets, usp are indicated for treatment of paget's disease of bone in men and women. the optimal duration of use has not been determined. t

États-Unis - anglais - NLM (National Library of Medicine)

macleods pharmaceuticals limited - montelukast (unii: mhm278sd3e) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium chewable tablet is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium chewable tablet is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium chewable tablet is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the benefits of montelukast sodium chewable tablets may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium chewable tablet is not indicated for the treatment of an acute asthma attack. montelukast sodium chewable tablets is contraindicated in patients with hypersensitivity to any of its components. risk su

États-Unis - anglais - NLM (National Library of Medicine)

macleods pharmaceuticals limited - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of: • major depressive disorder (mdd) [see clinical studies (14.1)] • generalized anxiety disorder (gad) [see clinical studies (14.2)] • social anxiety disorder (sad) [see clinical studies (14.3)] • panic disorder (pd) [see clinical studies (14.4)] venlafaxine hydrochloride extended-release capsules are contraindicated in patients: • with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation [see adverse reactions (6.2)]. • taking, or within 14 days of stopping, maois (including the maois linezolid and intravenous methylene blue) because of the risk of serotonin syndrome [see dosage and administration (2.11), warnings and precautions (5.2), and drug interactions (7.1)]. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including venlafaxine hydr